If you’ve ever compared notes with someone else using weight loss peptides, you may have noticed something surprising:
One person can barely eat… while another is still hungry on the same medication.
This isn’t unusual—it’s actually a reflection of how differently these compounds work in the body.
In this article, we’ll break down the key differences in appetite suppression between Semaglutide, Tirzepatide, and Retatrutide, and explore the growing interest in adding Cagrilintide to enhance appetite control.
Understanding the Core Mechanisms
To understand why appetite suppression varies, you first need to understand how each compound works.
Semaglutide (GLP-1 Only)
Semaglutide acts purely on the GLP-1 receptor, which is heavily involved in:
-
Appetite regulation in the brain
-
Slowing gastric emptying
-
Increasing satiety
👉 Result:
Strong, direct appetite suppression.
Many users report:
-
Reduced “food noise”
-
Feeling full quickly
-
Less interest in eating
Tirzepatide (GLP-1 + GIP)
Tirzepatide activates two pathways:
-
GLP-1 → appetite suppression
-
GIP → improved insulin sensitivity and metabolic function
👉 Result:
-
Strong appetite suppression
-
More stable blood sugar → fewer hunger spikes
Users often describe it as:
“Food becomes less important rather than completely unappealing.”
Retatrutide (GLP-1 + GIP + Glucagon)
Retatrutide introduces a third mechanism:
-
GLP-1 → appetite suppression
-
GIP → metabolic support
-
Glucagon → increased energy expenditure
This is a critical difference.
👉 Retatrutide is not just reducing intake—it’s also increasing calorie burn.
The Key Insight: More Fat Loss ≠ More Appetite Suppression
Retatrutide has shown the highest weight loss potential of the three, yet many users report:
“I’m still hungry—but I’m losing weight.”
Why?
Because the glucagon component increases metabolic rate and fat oxidation, meaning weight loss doesn’t rely solely on eating less.
In some cases, glucagon activity may even counterbalance appetite suppression slightly, which explains why not everyone experiences strong hunger reduction.
Why Appetite Suppression Varies Between People
If two people take the same compound but feel completely different effects, it usually comes down to:
1. Receptor Sensitivity
Some individuals respond strongly to GLP-1 signalling, while others don’t.
2. Baseline Metabolic State
Factors like:
-
insulin resistance
-
leptin resistance
-
chronic dieting
can influence hunger signals.
3. Hormonal Feedback
The body actively resists fat loss. In some individuals, hunger hormones remain elevated despite medication.
Appetite Suppression: A Practical Comparison
From real-world experience and clinical data patterns:
Strongest appetite suppression
→ Semaglutide
Balanced appetite + metabolic effect
→ Tirzepatide
Most powerful fat loss (but not always strongest appetite suppression)
→ Retatrutide
Where Cagrilintide Comes In
Cagrilintide is an analogue of amylin, a hormone released alongside insulin that plays a role in satiety.
It works differently from GLP-1 by:
-
Slowing gastric emptying
-
Increasing feelings of fullness
-
Reducing overall food intake
Proven Combination: Cagrilintide + Semaglutide
Clinical research on the combination often referred to as “CagriSema” has shown:
-
Significantly greater weight loss than semaglutide alone
-
Stronger appetite suppression
-
Complementary mechanisms (GLP-1 + amylin)
👉 This confirms that targeting multiple satiety pathways enhances results.
What About Cagrilintide + Retatrutide?
This is where things get interesting.
Currently:
-
There are no direct clinical trials on this combination
-
Use is based on mechanistic reasoning and experimental approaches
However, the logic is compelling:
Retatrutide already covers:
-
GLP-1
-
GIP
-
glucagon
But it does not include amylin activity.
👉 Adding cagrilintide could theoretically:
-
Increase satiety
-
Reduce hunger signals
-
Complement the metabolic effects of retatrutide
Who Might Benefit from Adding Cagrilintide?
This approach may be relevant for individuals who:
-
Still feel hungry on GLP-1-based treatments
-
Struggle with ongoing “food noise”
-
Are losing weight but find adherence difficult due to appetite
Important Considerations
While the combination is promising, it’s important to understand:
-
Evidence for semaglutide + cagrilintide is strong
-
Evidence for retatrutide + cagrilintide is still emerging
-
Individual response can vary significantly
Final Thoughts
Not all weight loss therapies work the same way—and more importantly, they don’t feel the same.
-
Some rely heavily on appetite suppression
-
Others combine appetite control with increased energy expenditure
This is why one person may feel dramatically reduced hunger, while another still experiences normal appetite—but continues to lose weight.
Understanding these differences allows for more targeted and effective approaches, especially when considering combination strategies like adding cagrilintide.
Key Takeaway
The most powerful fat loss compound is not always the strongest appetite suppressant.
And in cases where appetite suppression is lacking, targeting additional pathways like amylin may offer a valuable solution.
Disclaimer:
This article is for informational and educational purposes only. The compounds discussed are subject to ongoing research and are not universally approved for weight loss or general medical use in all regions. Always consult a qualified healthcare professional before considering any treatment or combination protocol.